No Data
No Data
Maxim Group Maintains Petros Pharmaceuticals(PTPI.US) With Buy Rating
Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
Express News | Petros Pharmaceuticals Inc : Maxim Group Cuts Target Price to $1 From $4
Petros Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results With Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (Avanafil)
No Data